Venous Thromboembolism Treatment Market by Device (Thrombectomy, Inferior Vena Cava Filter [Retrievable, Permanent], Stockings, Compression Pump) Application (DVT, Pulmonary Embolism) End User (Hospital, Ambulatory Care Center) – Global Forecast to 2030

Venous Thromboembolism Treatment Market by Device (Thrombectomy, Inferior Vena Cava Filter [Retrievable, Permanent], Stockings, Compression Pump) Application (DVT, Pulmonary Embolism) End User (Hospital, Ambulatory Care Center) – Global Forecast to 2030

Venous Thromboembolism Treatment Market by Device (Thrombectomy, Inferior Vena Cava Filter [Retrievable, Permanent], Stockings, Compression Pump) Application (DVT, Pulmonary Embolism) End User (Hospital, Ambulatory Care Center) — Global Forecast to 2030.

The global venous thromboembolism treatment market is projected to reach $4.40 billion by 2030, at a CAGR of 7.2% from 2023 to 2030.

After conducting an extensive primary and secondary study and an in-depth analysis of the market scenario, this report offers insights into the key drivers, constraints, challenges, and opportunities within the venous thromboembolism treatment market.

The high prevalence of venous thromboembolism, rising incidence of cancer, growing prevalence of secondary risk factors such as diabetes and obesity, increase in orthopedic surgical procedures, and the rising demand for minimally invasive treatment procedures are the key factors driving the growth of the venous thromboembolism treatment market. Furthermore, the growing accessibility and affordability of treatment options, advancements in VTE diagnosis and treatment methods, and the market expansion in emerging economies are expected to create market growth opportunities.

However, instances of product failure and product recalls may restrain the market’s growth. Additionally, lack of awareness about venous thromboembolism and increasing awareness of probable side effects of compression garments are major challenges for market growth.

Among the devices covered in this report, in 2023, the thrombectomy devices segment is expected to account for the largest share of the venous thromboembolism treatment market. The large market share of this segment is attributed to the increasing prevalence of cardiovascular diseases, growing preference for minimally invasive procedures, and launches of new thrombectomy devices.

Among the applications covered in this report, in 2023, the deep vein thrombosis segment is expected to account for the largest share of the venous thromboembolism treatment market. The large market share of this segment is attributed to the increasing prevalence of obesity, a growing geriatric population, rising cases of deep vein thrombosis due to lifestyle-related diseases, excessive alcohol consumption, and heightened awareness of DVT.

Among the end users covered in this report, in 2023, the hospitals segment is expected to account for the largest share of the venous thromboembolism treatment market. The large market share is attributed to the increasing prevalence of venous thromboembolism, the rising number of hospitals and clinics, the presence of highly skilled professionals, and the high purchasing power of hospitals. The easy accessibility to hospitals, coupled with a large patient population seeking comprehensive healthcare services, including diagnosis, treatment, and surgeries at a single location, also contributes to the significant market share of this segment.

An in-depth analysis of the geographical scenario of the global venous thromboembolism treatment market provides detailed qualitative and quantitative insights into the five major geographies: North America (U.S., Canada), Europe (Germany, France, U.K., Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India), Latin America, and the Middle East & Africa.

In 2023, North America is expected to account for the largest share of the global venous thromboembolism treatment market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. However, Asia-Pacific is slated to register the largest CAGR during the forecast period. The growth of this regional market can be attributed to factors such as the growing prevalence of chronic diseases, the increasing number of people living sedentary lifestyles, growing health expenditures, supportive government initiatives aimed at improving healthcare infrastructure, and rising awareness regarding venous thromboembolism.

The key players operating in the global venous thromboembolism treatment market are ALN Implants chirurgicaux (ALN Surgical Implants) (France), AngioDynamics, Inc. (U.S.), Argon Medical Devices, Inc. (U.S.), ArjoHuntleigh AB (Sweden), Boston Scientific Corporation (U.S.), Cardinal Health, Inc. (U.S.), Cook Group Incorporated (U.S.), Koninklijke Philips N.V. (Netherlands), DS MAREF Co., LTD (South Korea), Enovis Corporation (U.S.), LifeTech Scientific Corporation (China), Medtronic plc (Ireland), and Stryker Corporation (U.S.).

Scope of the Report:

Venous Thromboembolism Treatment Market Assessment—by Device

Thrombectomy Devices
Inferior Vena Cava Filters
Retrievable Filters
Permanent Filters
Stockings
Compression Pumps
Other Devices & Accessories

Note: Other devices & accessories include extraction and repositioning devices for vena cava filters and garments for compression therapy (excluding stockings).

Venous Thromboembolism Treatment Market Assessment—by Application

Deep Vein Thrombosis
Pulmonary Embolism

Venous Thromboembolism Treatment Market Assessment—by End User

Hospitals
Ambulatory Care Centers
Other End Users

Note: Other end users include nursing care centers, long-term care centers, and military health centers.

Venous Thromboembolism Treatment Market Assessment—by Geography

North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Rest of Europe (RoE)
Asia-Pacific (APAC)
China
Japan
India
Rest of APAC (RoAPAC)
Latin America
Middle East & Africa

Venous Thromboembolism Treatment Market - Report Summary

Report Metrics	Details
Years Considered	2021 - 2030
Base Year	2022
Forecast Period	2023-2030
Page Count	157
Units Referenced	Value (USD Million)
Segments/Key Topics	Market by Device, Application, End User, and Geography
Regions Covered	North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa
Key Companies Mentioned	ALN Implants chirurgicaux (France), AngioDynamics, Inc. (U.S.), Argon Medical Devices, Inc. (U.S.), ArjoHuntleigh AB (Sweden), Boston Scientific Corporation (U.S.), Cardinal Health, Inc. (U.S.), Cook Group Incorporated (U.S.), Koninklijke Philips N.V. (Netherlands), DS MAREF Co., LTD (South Korea), Enovis Corporation (U.S.), LifeTech Scientific Corporation (China), Medtronic plc (Ireland), and Stryker Corporation (U.S.)

FAQs About the Report

What is the scope of the venous thromboembolism treatment market study?

This market study covers the market sizes & forecasts of the venous thromboembolism treatment market based on device, application, end user, and geography. This market study also provides the value analysis of various segments and subsegments of the venous thromboembolism treatment market at the regional and country levels.

What is the revenue generated from the sales of venous thromboembolism treatment products across the globe? At what rate is their demand expected to grow for the next 5–7 years?

The venous thromboembolism treatment market is projected to reach $4.40 billion by 2030, at a CAGR of 7.2% during the forecast period of 2023–2030.

What are the various devices used in venous thromboembolism treatment, and which device segment holds the major share of the market?

Based on device, the venous thromboembolism treatment market is segmented into thrombectomy systems, inferior vena cava filters, stockings, compression pumps, and other devices. In 2023, the thrombectomy devices segment is expected to account for the largest share of the venous thromboembolism treatment market due to the increasing prevalence of cardiovascular diseases, growing preference for minimally invasive procedures, and the launch of new thrombectomy devices.

What are the applications of venous thromboembolism treatment products, and which application segment holds the major share of the market?

Based on application, the venous thromboembolism treatment market is segmented into deep vein thrombosis and pulmonary embolism. In 2023, the deep vein thrombosis segment is expected to account for the largest share of the venous thromboembolism treatment market. The large market share of this segment is attributed to the increasing geriatric population, rising cases of obesity, increasing cases of deep vein thrombosis due to disease-causing lifestyle, excessive alcohol consumption, and the growing awareness of DVT.

What are the various end users in the venous thromboembolism treatment market, and which end user segment holds the major share of the market?

Based on end user, the venous thromboembolism treatment market is segmented into hospitals, ambulatory care centers, and other end users. In 2023, the hospitals segment is expected to account for the largest share of the venous thromboembolism treatment market. The large market share is attributed to the increasing prevalence of venous thromboembolism, the rising number of hospitals and clinics, the presence of highly skilled professionals, and the high purchasing power of hospitals. The easy accessibility to hospitals, coupled with a large patient population seeking comprehensive healthcare services, including diagnosis, treatment, and surgeries at a single location, also contributes to the significant market share of this segment.

What are the key factors supporting the growth of this market? What are the major opportunities for the market players in the venous thromboembolism treatment market?

The high prevalence of venous thromboembolism, rising incidence of cancer, growing prevalence of secondary risk factors such as diabetes and obesity, increase in orthopedic surgical procedures, and the rising demand for minimally invasive treatment procedures are the factors driving the growth of the venous thromboembolism treatment market.

Furthermore, the growing accessibility and affordability of treatment options, advancements in VTE diagnosis and treatment methods, and the market expansion in emerging economies are expected to create market growth opportunities.

What are the factors hindering the growth of the venous thromboembolism treatment market?

Instances of product failure and product recalls may restrain the market’s growth. Additionally, lack of awareness about venous thromboembolism and increasing awareness of probable side effects of compression garments are major challenges for market growth.

Who are the major players operating in the venous thromboembolism treatment market?

The key players operating in the venous thromboembolism treatment market are ALN Implants chirurgicaux (France), AngioDynamics, Inc. (U.S.), Argon Medical Devices, Inc. (U.S.), ArjoHuntleigh AB (Sweden), Boston Scientific Corporation (U.S.), Cardinal Health, Inc. (U.S.), Cook Group Incorporated (U.S.), Koninklijke Philips N.V. (Netherlands), DS MAREF Co., LTD (South Korea), Enovis Corporation (U.S.), LifeTech Scientific Corporation (China), Medtronic plc (Ireland), and Stryker Corporation (U.S.).

Which regions/countries are expected to offer significant growth opportunities for the vendors operating in the venous thromboembolism treatment market?

Asia-Pacific is slated to register the largest CAGR during the forecast period and subsequently offer significant growth opportunities for the players operating in this market. The growth of this regional market can be attributed to factors such as the growing prevalence of chronic diseases, the increasing number of people living sedentary lifestyles, growing health expenditures, supportive government initiatives aimed at improving healthcare infrastructure, and rising awareness regarding venous thromboembolism.